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Bries De6ni t lve  Repor t  
Human Osteoblasts Support Hematopoiesis through 
the Production of Granulocyte Colony-stimulating 
Factor 
By Russell S. Taichman,* and Stephen G. Emerson~ 
From the Departments of *Periodontics, Prevention, and Geriatrics, and ~Internal Medicine, 
University of Michigan, Ann Arbor, Michigan 
Summary 
Previous attempts at identifying the constitutive source(s) of granulocyte colony-stimulating factor 
(G-CSF) in human bone marrow have been unsuccessful despite the fact that normal bone marrow 
supports abundant myelopoiesis in vivo. We hypothesized that the intimate physical association 
between bone and hematopoietic cells facilitates interactions between osteoblasts and hematopoietic 
stem cells. Here we provide the first direct evidence that human osteoblasts participate in 
hematopoiesis byconstitutively producing G-CSF and present the protein in a membrane-associated 
fashion to human hematopoietic progenitors. These results suggest a direct and central role for 
osteoblasts in normal myelopoiesis. 
H ematopoietic stem cell differentiation after birth is largely restricted to the bone marrow cavity. Whether osteo- 
blasts and bone matrix provide essential adhesive, stimula- 
tory, or regulatory signals to stem cells is not known. Overall, 
the unique physiological conditions that bone tissue provides 
for hematopoietic cells is essentially a mystery. Mesenchymal 
cells of fibroblast origin, dispersed throughout the marrow 
cavity, secrete cytokines such as GM-CSF, IL-6, and c-kit ligand 
to support basal hematopoiesis, and respond to inflamma- 
tory monokines by secreting large quantities of GM-CSF and 
G-CSF (1-7). This cytokine secretion profile is not, how- 
ever, specific tobone marrow and is shared by fibroblasts from 
many tissues. In addition, in the absence of inflammation 
human fibroblasts do not produce G-CSF, and the source of 
basal G-CSF production that supports normal granulopoi- 
esis is unknown (6, 7). 
The development of the bone marrow cavity is a coordi- 
nated process in which blood precursors migrate and colo- 
nize spaces carved out of embryonic bone and cartilage (8). 
Thus, an intimate physical association between bone cells and 
blood cells is established early in life. Since (a) osteoblasts 
are found on endosteal marrow surfaces; (b) primitive hema- 
topoietic stem cells are closely approximated with the en- 
dosteal surfaces rather than randomly distributed throughout 
the marrow cavity; and (c) many stromal cell lines hare sev- 
eral phenotypic haracteristics with osteoblasts (9-14), we 
hypothesized that osteoblasts might directly support stem 
cell survival and/or differentiation. In particular we asked 
whether osteoblasts might be a heretofore undetermined source 
of constitutively produced G-CSF in the bone marrow 
microenvironment. 
Materials and Methods 
Human Osteoblasts. "Human osteoblasts were obtained using a 
modification of methods described y Robey and Termine (15). 
Normal human trabecular bone was obtained from patients under- 
going orthopedic surgery in accordance with the University of 
Michigan's Policies for Human Subjects. Bone cleaned of loosely 
adherent tissue was ground to produce a uniform particle size (size 
~<1 mm 2) (BioComp MinimiU; W. Lorenz, Jacksonville, FL) and 
incubated in 1 mg/ml bacterial coUagenase (Type P; Boehringer 
Mannheim Biologicals, Indianapolis, IN). The explants were placed 
into culture until confluent monolayers were produced in a 1:1 
(vol/vol) mixture of F12/DMEM medium (Biofluids Inc., Rock- 
ville, MD) with low Ca +2 and 10% FCS. Thereafter, cultures 
were maintained in calcium-replete DMEM/F12 (1:1 vol/vol) 
medium containing 10% heat inactivated FCS, antibiotics, 10 mM 
B-glycerophosphate, and 10 mg/ml t-ascorbate. To verify that the 
cells were osteoblasts, several histochemical assays were performed 
including in vitro mineralization, and expression of high levels of 
alkaline phosphatase (16). 
RNA Preparation. Total cellular KNA was recovered from os- 
teoblasts as reported in (7). RNA quantity and integrity were 
checked by gel electrophoresis w th ethidium bromide and absor- 
bance at A~/A2s0. 
Oligonucleotide Primers. Sense and antisense primers were pre- 
pared by the oligonucleotide synthesis core at th  University of 
Michigan. The primers used in these investigations were reported 
previously (7) with the exceptions of those for osteocalcin (nu- 
cleotides 1046-1066 sense) GGCAGCGAGGTAGTGAAGAG 
and (nucleotides 1364-1384, antisense) GATGTGGTCAGCCA- 
ACTCGT. 
Reverse Transc@tase Polymerase Chain Reaction (RT-PCR). RT- 
PCtL was performed for35 cycles as previously reported (7). PCR 
products were electrophoresed in 3% agarose and visualized with
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ethidium bromide. As positive cytokine controls, RNA was iso- 
lated from either peripheral blood lymphocytes stimulated with 
PHA (3.0 #g/ml) and PMA (3 ng/ml) or IL-lc~ (25 U/m1) stimu- 
lated human bone marrow stromal cells. To control for DNA con- 
tamination, reverse transcriptase was omitted from the reverse tran- 
scriptase reaction. 
ELISAs. G-CSF ELISAs were performed using the double- 
antibody sandwich method (R&D Systems Inc., Minneapolis, MN). 
Based upon parallel assays of known diluted standards, the sensi- 
tivities of the assays for G-CSF in unconcentrated medium is 
25-2,000 pg/ml. Aliquots of conditioned medium were concen- 
trated 4-10-fold by centrifugation at 1,000 gin a 25~ fixed angle 
JA-17 rotor (Beckman Instruments Inc., Fullerton, CA) in Cen- 
tricon-10 concentrators (Amicon Division ofW. R. Grace and Co., 
Beverly, MA) until the desired volume was reached. Used in con- 
junction with concentrated medium, the G-CSF ELISA was able 
to detect concentrations as low as 4 pg/ml. 
Immunohistochemistry. Indirect immunohistochemistry phase- 
contrast microscopy was performed for G-CSF on 2% paraformalde- 
hyde-fixed primary human osteoblasts grown in 96-well tissue cul- 
ture plates. Paraformaldehyde-fixed primary human osteoblasts were 
incubated with 10/~g/ml of a murine monoclonal anti-human 
G-CSF in PBS (M7; kind gift of Dr. Michael Widmer, Immunex 
Corporation, Seattle, WA)or an isotype control (FOPC-21, Sigma 
Chemical Co., St. Louis, MO) at 4~ for two hours followed by
a rabbit antimurine FITC-conjugated serum at a 1/64 dilution 
(Sigma Chemical Co.). Nonspecific binding was blocked with 10% 
normal rabbit serum. 
Isolation of CD34 + Cells. Bone marrow cells obtained from 
healthy adult volunteers were diluted 1:4 (vol/vol) in IMDM and 
separated bydensity separation on Ficoll-Hypaque (specific gravity 
1.077) to recover mononuclear cells. After two rounds of plastic 
adherence at 370C for 1 h each in IMDM medium with 20% FCS 
(to remove monocytes, platelets, and megakaryocytes), the n nad- 
herent cells were recovered. CD34 § hematopoietic progenitor 
populations were isolated using an avidin-biotin immunoaffinity 
process (CellPro Inc., Bothell, WA). 
Coculture of NFS-60, CD34 +, and Osteoblasts. CD34 + or NFS- 
60 cells were seeded directly onto osteocalcin +, c-kit ligand- 
confluent osteoblast monolayers in 96-well tissue culture plates at 
a final density of 104 cells/well and incubated for 3-14 d. Either 
vehicle, 10 #g/weU of an a~nity purified IgG fraction of neutralizing 
goat anti-human G-CSF serum (R&D Systems), or 10/~g/well 
of normal goat IgG serum were added to cultures daily. Absolute 
cell numbers were determined by manual hemocytometer counting 
in PBS containing 0.4% trypan blue (Sigma Chemical Co.). 
Figure 1. RT-PCR detection fcytokine mRNA by (A) primary human 
osteoblasts and (B) stromal cells. RT-PCR was performed using primers 
for IL-Ic~, TNF, lymphotoxin (LT), IL-6, G-CSF, GM-CSF, IL-3, c-kit ligand, 
and osteocalcin. Negative controls omitted reverse transcriptase from the 
reverse transcription reaction. RNA from IL-13 and TNF-c~ stimulated 
stromal cells served as positive controls for G-CSF and c-kit ligand. 
Results and Discussion 
We first determined whether unstimulated primary human 
osteoblasts are a normal source of G-CSF. Primary osteoblasts 
were obtained using the methods of Robey and Termine (15), 
where osteoblasts emerge from collagenase-digested human 
bone during the second to third week of culture. We found 
that these cells express several functional characteristics ofos- 
teoblasts including the expression of mRNA for matrix Gla 
protein (not shown) and the osteoblast-specific protein, os- 
teocalcin (bone Gla protein) (16-18) (Fig. 1), mineralization 
of their extracellular matrix, and the expression of alkaline 
phosphatase examined by histochemical methods (data not 
shown) (16). 
Primary human osteoblast cultures were examined fortheir 
expression of mRNA for several cytokines using RT-PCR. 
As shown in Fig. 1, osteoblasts constitutively express mRNA 
for several cytokines including TNF-a, IL-6, GM-CSF, and 
G-CSF, but failed to express mRNA for IL-loe, IL-3, and 
c-kit ligand. As c-kit ligand is constitutively produced by 
stromal fibroblasts, the absence of detectable mRNA for this 
hematopoietic growth factor suggests minimal fibroblast con- 
tamination i  the primary cultures (Fig. 1 and 4, 6, 7). To 
further assure that these results are representative of normal 
osteoblast physiology, we induced the differentiation f os- 
teoblasts from nonadherent low density bone marrow os- 
teoprogenitors u ing a serum deprivation method (19). A 
similar cytokine profile was observed for these osteocalcin +, 
c-kit ligand- cells. In addition, we noted a comparable pat- 
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Figure 2. Immunohistochemical detection ofG-CSF on osteoblast cell surfaces. 2% paraformaldehyde-fixed primary human osteoblasts (A) were in- 
cubated with (C) 10/~g/ml ofroutine monoclonal anti-human G-CSF in PBS or (B) an isotype control at 4~ for 2 h followed by a rabbit antimurine 
FITC-conjugated serum at a 1:64 dilution (Sigma Chemical Co.). Nonspecific binding was blocked with 10% normal rabbit serum. 
tern of cytokine mRNAs expressed by the human osteosar- 
coma cell lines, MG-63 and SaOSo2 (data not shown). 
The ILT-PCR results uggest that osteoblasts constitutively 
express G-CSF mRNA. We next asked whether the G-CSF 
message is translated and how the protein is presented toheo 
matopoietic progenitors. To determine whether the G-CSF 
message is translated, we performed immunohistochemical 
staining for G-CSF on paraformaldehyde-fixed primary human 
osteoblasts u ing a monoclonal nti-human G-CSF antibody. 
As shown in Fig. 2, G-CSF is localized on the cell membrane 
of the osteoblasts and not in the interstitial extracellular ma- 
trix. To quantify G-CSF production from unstimulated os- 
teoblasts expressing G-CSF mRNA, salt extracts of extracel- 
lular matrix (20, 21) and concentrated, conditioned medium 
were analyzed for G-CSF by ELISA (7). As positive controls 
for G-CSF production, osteoblasts or stromal cells were ex- 
posed to lipopolysaccharide or IL-lc~, respectively (22-24). 
LPS stimulation of osteoblasts resulted in the production of 
21 pg/ml/24 h/104 cells of soluble G-CSF. No G-CSF could 
be detected in the medium or extracellular matrix of unstimu- 
lated osteoblasts, uggesting that under basal conditions G- 
CSF may not be released as a soluble protein. 
To determine whether the G-CSF detected by immuno- 
histochemical methods has functional activity, we evaluated 
the proliferation of the G-CSF-dependent cell line NFS-60 
in coculture with osteocalcin +,c-kit ligand- human explant 
osteoblasts (25). A neutralizing antibody to human G-CSF 
was used to directly test whether osteoblast-derived G-CSF 
has biological activity. As shown in Fig. 3, NFS-60 cells 
proliferate in the presence of osteoblast monolayers but not 
in medium alone. Inclusion of a neutralizing anti-G-CSF an- 
tibody in the cultures caused a41% reduction in the prolifer- 
ation of the NFS-60 cells. The proliferation of NFS-60 cells 
was not affected by a control antiserum nor were significant 
differences in proliferation of the NFS-60 cells observed when 
the cells were grown in osteoblast-conditioned m ium (50% 
vol/vol) alone, with or without he neutralizing anti-human 
G-CSF antibody. 
These results obtained with the NFS-60 cell line suggest 
that osteoblasts might stimulate the proliferation of human 
o~ 
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Figure 3. NFS-60 cell proliferation osteoblast monolayers. NFS-60 
cells were seeded onto confluent human osteoblasts at a final density of 
104 cells/well in 96-well tissue culture plates for 3 d. Where indicated ve- 
hicle (no AB), 10/zg/well ofan affinity purified IgG fraction of neutralizing 
goat anti-human G-CSF serum (Anti-G-CSF) or 10/~g/we11 of normal 
goat IgG serum (control AB) were added aily. Absolute NFS-60 cell 
numbers were determined by manual hemocytometer counting and reported 
as mean _+ SD (n = 4). (Asterisk) Significant difference from antibody 
or vehicle control, p <0.01. 
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Figure 4. Human CD34 § cells obtained by affinity purification of
nonadherent low density mononuclear bone marrow cells (CellPro Inc.) 
were seeded directly into 96-well tissue culture plates or onto confluent 
osteocalcin + c-kit ligand- human osteoblast monolayers at a final den- 
sity of 104 cells/well and incubated for 14 d. The Results ofone of two 
experiments are presented. Where indicated vehicle (no AB), 10/Lg/well 
of either neutralizing goat anti-human G-CSF serum or goat IgG serum 
(control AB) were added aily (R&D Systems). Cell counts were deter- 
mined by manual hemocytometer counting and are reported asmean -+ SD 
(n = 3). The hematopoietic cells recovered after 2 wk of coculture main- 
tained an immature (23 _+ 6% myeloblasts/promyelocytes; 51.7 + 5.5% 
myelocytes/metamyelocytes; 21 + 5%bands/polymorphonudear neutro- 
phils; and 4.3 _+ 0.6% monocytes, treatment with anti-G-CSF reduced 
the recovery of band/polymorphonuclear neut ophils to8.7 _+ 10%). 
(Asterisk) Significant difference from antibody orvehicle control, p <0.01. 
hematopoietic progenitors by producing G-CSF. To examine 
this possibility, CD34 + hematopoietic progenitor cells were 
isolated and seeded into confluent osteocalcin +, c-kit ligand- 
osteoblast monolayers. At 14 d the hematopoietic cells were 
recovered and counted. The significance of G-CSF in this 
system was tested by the addition of an antiserum to human 
G-CSF. An eightfold increase in cell recovery was observed 
for hematopoietic cells grown in coculture with osteoblasts 
over a 2-wk period (Fig. 4). 55.4% of the osteoblast-induced 
increase in cell recovery was directly blocked by coincuba- 
tion of neutralizing anti-G-CSF antibody in the culture. It 
is interesting that 44.5% of the growth activity produced 
by osteoblasts was not due to G-CSF, either alone or in com- 
bination with other osteoblast-derived cytokines. Further- 
more, in Wright-Geimsa cytospin preparations many of the 
hematopoietic cells recovered after 2 wk of coculture main- 
tained an immature morphology (23 _ 6% myeloblasts/ 
promyelocytes; 51.7 _+ 5.5% myelocytes/metamyelocytes; 
21 _+ 5% bands/polymorphonudear n utrophils; 4.3 _ 0.6% 
monocytes). These data suggest that osteoblasts might pro- 
duce additional factors that support he survival and limited 
proliferation of primitive myeloid cells as well. 
The biologic data using CD34 + and the NFS-60 cell line 
in conjunction with the mRNA, and immunohistochemistry 
results strongly suggest hat human osteoblasts produce 
G-CSE Osteoblast-derived G-CSF appears to be accessible 
to target cells when it is associated with osteobhst's ceil mem- 
brane. The possible mechanisms by which growth factors be- 
come cell associated or retained by components of the ex- 
tracellular matrix and presented to target cells have not yet 
been fully elucidated. Cell associated forms of M-CSF, c-kit 
ligand, IL-lol, and matrix-associated forms of IL-3 and GM- 
CSF have been described (20, 21, 25-30). The implications 
of the experiments evaluating G-CSF production with bio- 
assays vs. ELISA of conditioned osteoblast medium suggest 
that either (a) immunoreactive G-CSF is diffusible only over 
extremely short distances before inactivation; (b) the neu- 
tralizing G-CSF antibody does not have access to the microen- 
vironment between osteoblasts and stem ceils; (c) directed 
cell-cell transfer of G-CSF occurs between the osteoblasts 
and hematopoietic progenitors, as has been reported for IL-2 
(31); or (d) G-CSF or a closely related molecule is presented 
to hematopoietic cells as a cell membrane associated protein 
or bound in an active form to extracellular matrix molecules. 
Of interest, at least hree forms of G-CSF have been identified 
on immunoblots, including 18-, 28-, and 32-kD forms (32). 
To date it appears that the major secreted species is the 18-kD 
form, whereas the biological nature of the higher molecular 
mass proteins are unknown but possibly represent cell- 
associated or inactive protein precursors (32). We found no 
evidence for G-CSF detectable in either the LPS-treated or 
untreated osteoblast matrix fraction; until more extensive in- 
vestigation of osteoblast's extracellular mat ix is performed 
however, these data do not rule out such a possibility. 
It is interesting that the antibody to G-CSF neutralized 
only 55% of the CD34 + cell's proliferative activity pro- 
duced by the osteoblasts (Fig. 4). Thus, more than one factor 
produced by osteoblasts may support the proliferation of he- 
matopoietic stem cells. At present we do not know the iden- 
tity of the molecule(s) which are responsible for this activity. 
In preliminary experiments neutralizing antibody to IL-6 and 
GM-CSF failed to affect proliferation of the NFS-60 cell ine. 
It is possible that unique osteoblast-derived cytokines are 
responsible for proliferative effects on NFS-60 and CD34 + 
cells. These observations suggest that stem cell self-renewal 
is influenced by either osteoblast-derived cytokines or adhe- 
sive interactions between the two cell types or possibly both. 
In sum, strong evidence indicates that human osteoblasts 
produce cytokine signals that regulate hematopoiesis. Hema- 
topoietic myeloid stem cell differentiation occurs i direct prox- 
imity to osteoblasts within the bone marrow cavity. We spec- 
ulate that this intimate physical association established early 
in life facilitates interactions between bone and hematopoi- 
etic cells. We determined that human osteoblasts are a con- 
stitutive source of the hematopoietic growth factor G-CSF. 
If osteoblasts are a major source of the colony stimulating 
cytokines in bone marrow, then understanding of the regu- 
lation of osteoblast-elaborated cytokines and the functional 
consequences of alterations inosteoblast metabolism are critical 
to our understanding of normal hematopoiesis. 
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